| Drug-Target Information | ||||||||
|---|---|---|---|---|---|---|---|---|
| Drug Name | Target Name | Drug Type | Target Type | Source | Drug MeSHID | Interaction Score | Drug Status | Target Action |
| bvd-523 | ephrin type-b receptor 2 | NA | Clinical trial target | TTD , DGIDB | Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Malignant neoplasm of pancreas[MeSHID:D010190] melanoma[MeSHID:D008545] Pancreatic carcinoma[MeSHID:C562463] Malignant Neoplasms[MeSHID:D009369] |
5.3 | phase 2 | unknown |
| bvd-523 | extracellular signal-regulated kinase 2 | NA | Clinical trial target | TTD , DGIDB | Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Malignant neoplasm of pancreas[MeSHID:D010190] melanoma[MeSHID:D008545] Pancreatic carcinoma[MeSHID:C562463] Malignant Neoplasms[MeSHID:D009369] |
0.4 | phase 2 | unknown |
| bvd-523 | extracellular signal-regulated kinase 1 | NA | Clinical trial target | TTD , DGIDB | Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Malignant neoplasm of pancreas[MeSHID:D010190] melanoma[MeSHID:D008545] Pancreatic carcinoma[MeSHID:C562463] Malignant Neoplasms[MeSHID:D009369] |
1.59 | phase 2 | unknown |
| click here to return to the previous page | ||||||||